FGR Inhibitors
1 drugsAbout FGR
FGR (Feline Gardner-Rasheed Sarcoma Viral Oncogene Homolog) is a non-receptor tyrosine kinase involved in cell signaling pathways that regulate cell growth, differentiation, and survival. Aberrant activation of FGR can contribute to cancer development.
FGR has emerged as a therapeutic target in oncology. However, there is currently no genetic evidence available linking FGR to specific diseases, highlighting the need for further investigation.
There is one FDA-approved drug, ZELBORAF (Roche), targeting FGR for oncology indications. ZELBORAF is a small molecule approved in 2011.
Top FGR Drugs
Roche is the only company with an approved drug targeting FGR.
The market is not crowded, presenting an opportunity for new entrants if FGR is a viable target.
FGR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets FGR, using small molecule modality.
Explore novel modalities like antibodies or PROTACs to differentiate from existing therapies.
FGR Clinical Trials 121 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FGR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 46 | 28 | 15 | 2 | 65% |
| Phase 2 | 61 | 25 | 14 | 22 | 64% |
| Phase 3 | 10 | 7 | 1 | 2 | 88% |
| Phase 4 | 4 | 2 | 1 | 1 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved FGR drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting FGR. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
FGR Drug Approval Timeline (2011 - 2011)
The first and only drug, ZELBORAF, was approved in 2011.
The approval timeline suggests potential saturation; consider combination therapies or new indications.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 66 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FGR. A trial counts if an approved drug acting on FGR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.